Literature DB >> 28948964

Authors' Response.

Abhijit Chaudhury1, A Shobha Rani1, Usha Kalawat1, Sachin Sumant1, Anju Verma1, B Venkataramana1.   

Abstract

Entities:  

Year:  2017        PMID: 28948964      PMCID: PMC5644308          DOI: 10.4103/0971-5916.215558

Source DB:  PubMed          Journal:  Indian J Med Res        ISSN: 0971-5916            Impact factor:   2.375


× No keyword cloud information.
We thank the authors of the letter1 for going through our article and welcome the comments made. First, the authors have raised the appropriateness of including Candida as a pathogen for ventilator associated pneumonia (VAP), since it is extremely rare and lung biopsy is the only definitive method for diagnosis of Candida pneumonia. Earlier, the data from 24 investigations conducted with ventilated patients for a total of 1,689 episodes and 2,490 pathogens revealed Candida as an aetiological agent in 0.9 per cent2 while in our study, it was 2.0 per cent (63 out of 3084 clinically suspected cases)3 which may not be termed substantially high. We agree that the existing bronchoscopic or non-bronchoscopic specimens are not appropriate for diagnosis of Candida pneumonia and Candida recovered from such samples signifies colonization. However, it has been found in several studies that it is not an innocuous colonizer and Candida trachea-bronchial colonization increases the risk for subsequent Pseudomonas aeruginosa VAP as well as the risk for infection with other multidrug resistant bacteria456. In view of this, it becomes necessary to report Candida biofilm infection in VAP patients irrespective of whether or not it is the aetiological agent of pneumonia. This is important since antifungal therapy could potentially reduce the risk for bacterial infection7. Secondly, our study has revealed a high rate of VAP and similar observations have been made in other Indian studies as well, as mentioned in our article3. Our study has focussed on the profile of the pathogens rather than the patients. So it is understandable that we have not looked into the patient profile and the other co-morbid conditions and risk factors which can predispose to VAP. Finally, the authors have touched upon a very relevant aspect regarding the organizational setup in a hospital for the care of the critically ill patients, which include the patients on mechanical ventilation. Needless to say, our hospital like any other government referral hospital in India is overburdened with patients. The necessary nurse-to-patient ratio and other recommendations which have been formulated by the industrialized countries cannot be followed completely, the reason being multi-factorial. Educational component is a defining factor, since a great majority of nurses working in these intensive care units (ICU) may be without specialized training. In our hospital, the infection control committee takes the initiative to teach the nursing staff about the care of the critically ill patients on a periodic basis. The situation may be somewhat better in corporate hospitals with adequate staff and better infrastructure. Some of these also run their own diploma or certificate courses in critical care nursing, and the trained personnel are absorbed by them or other similar hospitals. The government of India has taken the initiative to introduce post-graduate residency programme (M. Sc) in Critical Care Nursing (Nurse Practitioner) as part of the National Health Policy, 20158 and the draft curriculum has already been prepared and endorsed by the Indian Nursing Council9. Such measure can slowly change the present scenario, and it is expected that improved patient care will help in bringing down the unusually high VAP rates seen in the Indian setting.
  7 in total

1.  Candida colonization in ventilated ICU patients: no longer a bystander!

Authors:  Jean-Damien Ricard; Damien Roux
Journal:  Intensive Care Med       Date:  2012-06-15       Impact factor: 17.440

2.  Candida colonization of the respiratory tract and subsequent pseudomonas ventilator-associated pneumonia.

Authors:  Elie Azoulay; Jean-François Timsit; Muriel Tafflet; Arnaud de Lassence; Michael Darmon; Jean-Ralph Zahar; Christophe Adrie; Maité Garrouste-Orgeas; Yves Cohen; Bruno Mourvillier; Benoît Schlemmer
Journal:  Chest       Date:  2006-01       Impact factor: 9.410

Review 3.  Ventilator-associated pneumonia.

Authors:  Jean Chastre; Jean-Yves Fagon
Journal:  Am J Respir Crit Care Med       Date:  2002-04-01       Impact factor: 21.405

4.  Candida spp. airway colonization: A potential risk factor for Acinetobacter baumannii ventilator-associated pneumonia.

Authors:  Xiaojiang Tan; Song Zhu; Dongxing Yan; Weiping Chen; Ruilan Chen; Jian Zou; Jingdong Yan; Xiangdong Zhang; Dimitrios Farmakiotis; Eleftherios Mylonakis
Journal:  Med Mycol       Date:  2016-03-21       Impact factor: 4.076

5.  Evaluating rates of ventilator-associated pneumonia: Consider patient, organizational & educational risk factors.

Authors:  Despoina Koulenti; Carole Boulanger; Stijn Blot
Journal:  Indian J Med Res       Date:  2017-05       Impact factor: 2.375

6.  Antibiotic resistance & pathogen profile in ventilator-associated pneumonia in a tertiary care hospital in India.

Authors:  Abhijit Chaudhury; A Shobha Rani; Usha Kalawat; Sachin Sumant; Anju Verma; B Venkataramana
Journal:  Indian J Med Res       Date:  2016-09       Impact factor: 2.375

7.  Impact of antifungal treatment on Candida-Pseudomonas interaction: a preliminary retrospective case-control study.

Authors:  Saad Nseir; Elsa Jozefowicz; Béatrice Cavestri; Boualem Sendid; Christophe Di Pompeo; Florent Dewavrin; Raphaël Favory; Micheline Roussel-Delvallez; Alain Durocher
Journal:  Intensive Care Med       Date:  2006-11-08       Impact factor: 17.440

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.